Diagnostic transcript and splice patterns of HR-HPV in different cervical lesions

Patent metadata

Field	Value
Publication number	US-10731228-B2
Application number	US-201715788165-A
Country	US
Kind code	B2
Filing date	Oct 19, 2017
Priority date	May 5, 2010
Publication date	Aug 4, 2020
Grant date	Aug 4, 2020

Abstract

The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.

First claim

The invention claimed is:

1. A method for identifying a subject with HR-HPV having a severe form of HR-HPV infection, said subject not comprising the HR-HPV genome in an integrated form, comprising the steps:
a) determining, in a sample of said subject, the presence of a gene product of E1C, said gene product of E1C being a spliced transcript of E1 which has been spliced to comprise a splice junction which has a splice donor site at a position between positions 800 and 1000 and a splice acceptor site between positions 2400 and 2900, wherein the determining of said transcript comprises the steps of amplifying said transcript with oligonucleotides that specifically amplify said transcript and hybridizing said amplified transcript with a probe oligonucleotide that specifically binds to the nucleotides flanking the splice junction, thereby detecting said splice junction and determining the presence of the amplified transcript-probe complex, and
b) based on the result of the determination of step a), identifying a subject with HR-HPV having a severe form of HR-HPV infection
wherein the HR-HPV is HPV33 and the corresponding spliced transcript of E1 is a spliced transcript comprising a 894{circumflex over ( )}2702 junction, and
wherein the probe oligonucleotide comprises SEQ ID NO: 11.

2. The method of claim 1 , wherein the presence of a gene product of E1C indicates a severe form of HR-HPV infection.

3. The method of claim 1 , wherein determining the presence of a spliced transcript of E1 comprises PCR amplification of said spliced transcript of E1.

4. The method of claim 3 , wherein PCR amplification makes use of a mixture of primers.

5. The method of claim 1 , wherein the presence of the transcript is determined by using a probe oligonucleotide that specifically detects the said transcript.

6. The method of claim 1 , comprising the further step of assessing in said sample of said subject the integration status of the HR-HPV genome.

7. A method for identifying a subject with HR-HPV having a severe form of HR-HPV infection, said subject not comprising the HR-HPV genome in an integrated form, comprising the steps:
a) determining the amount of a first gene product in a sample of said subject, said first gene product being a gene product of E1C, said gene product of E1C being a spliced transcript of E1 which has been spliced to comprise a splice junction which has a splice donor site at a position between positions 800 and 1000 and a splice acceptor site between positions 2400 and 2900, wherein the determining of said transcript comprises the steps of amplifying said transcript with oligonucleotides that specifically amplify said transcript and hybridizing said amplified transcript with a probe oligonucleotide that specifically binds to the nucleotides flanking the splice junction, thereby detecting said splice junction and determining the presence of the amplified transcript-probe complex,
wherein the HR-HPV is HPV33 and the corresponding spliced transcript of E1 is a spliced transcript comprising a 894{circumflex over ( )}2702 junction, and
wherein the probe oligonucleotide comprises SEQ ID NO: 11,
b) determining the amount of a second gene product in said sample,
c) calculating a ratio of the amount of said first gene product as determined in step a) and the amount of said second gene product as determined in step b),
d) comparing the ratio as calculated in step c) to a reference ratio, and
e) based on the result of the comparing of step d), identifying a subject with HR-HPV having a severe form of HR-HPV infection.

8. The method of claim 7 , wherein the second gene product is a transcript of Ubc.

9. The method of claim 7 , wherein the ratio of the amount of said first gene product to the amount of said second gene product is calculated, and wherein (i) a ratio larger than the reference ratio indicates a severe form of HR-HPV infection.

10. The method of claim 7 , comprising the further step of assessing in said sample of said subject the integration status of the HR-HPV genome.

Assignees

• Deutsches Krebsforsch

Inventors

• Schmitt Markus
• Gissmann Lutz
• Pawlita Michael
• Hoefler Daniela

Classifications

• C07K16/084

  Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus · CPC title

• C12Q1/708 Primary

  for papilloma · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/158

  Expression markers · CPC title

• C12Q1/6883

  for diseases caused by alterations of genetic material · CPC title